RecruitingNCT06041893
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Haploidentical Hematopoietic Stem Cell Transplantation With Early Antithymocyte Globulin and Low Dose Post-transplant Cyclophosphamide
Sponsor
Samsung Medical Center
Enrollment
20 participants
Start Date
May 29, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.
Eligibility
Inclusion Criteria1
- Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center.
Exclusion Criteria1
- A clinical trial subject (legal representative, if applicable) who do not consent or is unable to give written consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGATG-LDPTCy
antithymocyte globulin with low dose post-transplant cyclophosphamide
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06041893